Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary disease ...

The active ingredient in Nucala is mepolizumab. (An active ingredient is what makes a drug work.) Nucala is given as an injection under your skin. A healthcare professional may give you these ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

Patients began with mepolizumab or benralizumab before switching to continuing with benralizumab at week 52. About 44% of patients stopped using oral glucocorticoids. Blood eosinophil counts fell ...

Depemokimab’s mechanism of action is similar to mepolizumab. Three adverse events led to discontinuation or withdrawal. 72% of patients were exacerbation-free, and 96% did not need a hospital or ...

(Alliance News) - GSK PLC on Monday said it has had an application to expand the use of mepolizumab for the treatment of chronic obstructive pulmonary disease accepted for review by the European ...

The FDA is reviewing the BLA for mepolizumab, an interleukin-5 (IL-5) antagonist monoclonal antibody, as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD ...

GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or mepolizumab, to include patients with chronic obstructive pulmonary disease (COPD) ...